A Prospective Investigation Using the Expired Breath Ethanol Test
Is Absorption of Irrigation Fluid a Problem in Thulium Laser Vaporization of the Prostate? A Prospective Investigation Using the Expired Breath Ethanol Test.
Benign prostatic hyperplasia (BPH) is a prevalent entity, affecting over 50% of men older than 60 years.In cases with moderate to severe lower urinary tract symptoms (LUTS) monopolar transurethral resection of the prostate (TUR-P) is the standard treatment. Especially in frail patients, conventional TUR-P is associated with relevant and potentially deleterious complications, e.g. TUR syndrome. Using isotonic saline, like in bipolar TUR-P and transurethral laser vaporization (TUV-P), TUR syndrome can be prevented.
The short-term complication rate with the Thulium laser is similar to the rate described after vaporisation with other laser systems18-23 and less than that with TUR-P.
Despite recent publications on the safety and complications with Thulium vaporisation of the prostate, to the investigators knowledge, until now, no prospective trial has directly assessed, whether absorption of irrigation fluid occurs and to what extent in Thulium Laser vaporisation of the prostate.
The investigators therefore aim to investigate if absorption of irrigation fluid occurs during Thulium Laser vaporisation of the prostate by expired breath ethanol test.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Benign prostatic hyperplasia (BPH) is a prevalent entity, affecting over 50% of men older than 60 years.3 The clinical picture of the disease includes lower urinary tract symptoms such as interrupted and weak urinary stream, nocturia, urgency and leaking and even sexual dysfunction in some individuals. Medical therapy is usually the first-line treatment. However, the efficacy of drugs like alpha-blockers is limited, and as disease progresses more invasive treatment options have to be taken into consideration.
In cases with moderate to severe lower urinary tract symptoms (LUTS) monopolar transurethral resection of the prostate (TUR-P) is the standard treatment. Especially in frail patients, conventional TUR-P is associated with relevant and potentially deleterious complications.
The proportion of elderly patients on anticoagulation or antiplatelet therapy with cardial comorbidities increases. Especially major bleeding and transurethral resection syndrome (TUR syndrome) put these high-risk patients at a relevant perioperative risk.
TUR syndrome is caused by absorption of electrolyte-free irrigating fluid (which has to be used in monopolar TUR-P), and consists of symptoms from the circulatory and nervous systems. Mild forms are common and often go undiagnosed, while severe forms of the TUR syndrome are potentially life-threatening.
Using isotonic saline, like in bipolar TUR-P and transurethral laser vaporization (TUV-P), TUR syndrome can be prevented. Moreover, these techniques were thought to completely prevent influx of irrigation fluid into the vascular system due to their excellent coagulation properties.
However, the Zürich study group has demonstrated that in bipolar resection of the prostate and with the Greenlight-Laser, significant intraoperative fluid absorption can occur. The authors emphasized, that care must be taken if using this procedures in patients with significant cardiovascular comorbidities, as large volume influx in patients with significant cardiac comorbidities could result in dangerous complications.
Ethanol monitoring was first used in the late 1980's as an alternative to traditional methods of measuring fluid absorption (i.e. measuring volumetric fluid balance and serum sodium concentration). These techniques, however, are bothersome and must be carried out meticulously to yield a valid figure of absorption. If a tracer amount of ethanol is added to the irrigation fluid, the volume of fluid absorbed can be estimated from the amount of ethanol measured in the patients' exhaled breath.
The expired-breath ethanol technique is an established method of investigating intra operative absorption of irrigation fluid. Ethanol 1% is added to conventional isotonic 0.9% saline for use as intra-operative irrigation. The absorption of irrigation fluid can be estimated by measuring the end-expiratory ethanol concentrations with an alcometer.
During the last years, the Thulium laser has emerged as an alternative to other types of lasers, combining the best features for performing vaporisation techniques: Thulium laser has a wavelength of 2013 nm, and its target chromophore is water. The energy of the Thulium laser has a high tissue absorption rate, producing effective vaporisation with scant depth in the remaining tissue. As the properties of water remain unaltered until it reaches boiling point, the effect of the laser on the tissue remains constant throughout the surgical procedure.
The short-term complication rate with the Thulium laser is similar to the rate described after vaporisation with other laser systems and less than that with TUR-P. Thus, Thulium vaporisation of prostate has established as a standard procedure in many urological departments including ours.
Despite recent publications on the safety and complications with Thulium vaporisation of the prostate, to the investigators knowledge, until now, no prospective trial has directly assessed, whether absorption of irrigation fluid occurs and to what extent in Thulium Laser vaporisation of the prostate.
The investigators therefore aim to investigate if absorption of irrigation fluid occurs during Thulium Laser vaporisation of the prostate by expired breath ethanol test.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
St. Gallen, Switzerland, 9007
- Cantonal Hospital St. Gallen
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Men older than 40
- Patient must be a candidate for TUV-P
- Refractory to medical therapy or patient is not willing to consider (further) medical treatment
- Written informed consent
Exclusion Criteria:
- Mild symptoms (IPSS <8)
- Urethral stenosis
- Bladder diverticulum (>100ml)
- Former alcoholic or chronic liver disease
- Alcohol consumption 24h before operation
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
patients with BPH undergoing TUV-P
patients with Benign Prostatic Hyperplasia undergoing TUV-P
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Absorption volume of irrigation fluid during the Thulium laser TUV-P
Time Frame: shortly after Thulium laser TUV-P
|
shortly after Thulium laser TUV-P
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Duration of surgery
Time Frame: at time of start and of end of surgery
|
at time of start and of end of surgery
|
|
|
Does absorption of irrigation fluid occur?
Time Frame: at time of surgery
|
yes: any detection of alcohol in the expired breath
|
at time of surgery
|
|
Assessment of bleeding and relevant intraoperative events (capsular perforation, injury to prostatic sinuses or deep bladder neck incision) by the surgeon
Time Frame: at time of surgery
|
at time of surgery
|
|
|
Amount of laser energy used intraoperatively (kilojoules)
Time Frame: at time of end of surgery
|
at time of end of surgery
|
|
|
Pre- to postoperative changes in serum biochemical and haematological variables (creatinin, sodium, potassium, chloride), venous pH, haemoglobin
Time Frame: 30 min after intervention
|
30 min after intervention
|
|
|
Pre- to postoperative changes in flow and residual urine
Time Frame: 12 weeks after intervention
|
12 weeks after intervention
|
|
|
Total irrigation volume and volume of all administered i.v. fluids
Time Frame: at time of end of surgery
|
at time of end of surgery
|
|
|
Duration of hospitalization post procedure
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 1 week
|
participants will be followed for the duration of hospital stay, an expected average of 1 week
|
|
|
Duration of post procedure catheterization
Time Frame: at time of end of catheterization, an expected average of 48 hrs
|
at time of end of catheterization, an expected average of 48 hrs
|
|
|
Pre- to postoperative changes in the IPSS
Time Frame: 12 weeks after intervention
|
12 weeks after intervention
|
|
|
Pre- to postoperative changes in bladder diary
Time Frame: 12 weeks after intervention
|
12 weeks after intervention
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Adverse events categorised according to the NCI-CTAE in grade 1 to 5
Time Frame: week 12
|
week 12
|
|
Grading of complications according to Clavien classification
Time Frame: week 12
|
week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Daniel Engeler, MD, Cantonal Hospital St. Gallen
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CTU 14.012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Benign Prostatic Hyperplasia (BPH)
-
NCT07381127RecruitingBPH | BPH (Benign Prostatic Hyperplasia) | BPH With Other Lower Urinary Tract Symptoms
-
NCT01566292CompletedBenign Prostatic Hyperplasia (BPH) | Benign Prostatic Enlargement (BPE)
-
NCT07592299Not yet recruiting
-
NCT07583706Recruiting
-
NCT07565961RecruitingBPH (Benign Prostatic Hyperplasia)
-
NCT07350005Not yet recruitingBPH (Benign Prostatic Hyperplasia)
-
NCT07623239Not yet recruitingBPH (Benign Prostatic Hyperplasia)
-
NCT07466030Not yet recruitingBPH (Benign Prostatic Hyperplasia)
-
NCT07277556Not yet recruitingBenign Prostatic Hyperplasia (BPH)